World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 95 9970 9354 5131 4740 303 37821

Richard L. Theriault publications per year

The chart shows the history of publications by Richard L. Theriault between 1983 and 2024, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Richard L. Theriault published across 42 years, from 1983 to 2024, averaging 7.2 papers a year. Output peaked at 25 publications in 2005. 1 of the 303 publications appeared in the last two years.

No. of publications
5 10 15 20 25
Bar chart. Horizontal axis: year, 1983 to 2024. Vertical axis: number of publications, 0 to 25. Peak 25 publications in 2005. 1983: 1 publication 1984: 1 publication 1985: 0 publications 1986: 1 publication 1987: 0 publications 1988: 1 publication 1989: 3 publications 1990: 5 publications 1991: 6 publications 1992: 8 publications 1993: 5 publications 1994: 10 publications 1995: 7 publications 1996: 5 publications 1997: 8 publications 1998: 5 publications 1999: 14 publications 2000: 12 publications 2001: 8 publications 2002: 8 publications 2003: 14 publications 2004: 15 publications 2005: 25 publications 2006: 16 publications 2007: 10 publications 2008: 10 publications 2009: 15 publications 2010: 13 publications 2011: 19 publications 2012: 14 publications 2013: 15 publications 2014: 11 publications 2015: 8 publications 2016: 4 publications 2017: 2 publications 2018: 2 publications 2019: 0 publications 2020: 1 publication 2021: 0 publications 2022: 0 publications 2023: 0 publications 2024: 1 publication
1983 2024

303 publications in total across all disciplines

View publications per year as a table
Richard L. Theriault: publications per year, 1983 to 2024
Year Publications
1983 1
1984 1
1985 0
1986 1
1987 0
1988 1
1989 3
1990 5
1991 6
1992 8
1993 5
1994 10
1995 7
1996 5
1997 8
1998 5
1999 14
2000 12
2001 8
2002 8
2003 14
2004 15
2005 25
2006 16
2007 10
2008 10
2009 15
2010 13
2011 19
2012 14
2013 15
2014 11
2015 8
2016 4
2017 2
2018 2
2019 0
2020 1
2021 0
2022 0
2023 0
2024 1
Total 303
Download as CSV

Richard L. Theriault publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard L. Theriault sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 301–320 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 303 publications — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834 303
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Richard L. Theriault D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard L. Theriault sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 94–95 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808 95
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Richard L. Theriault is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research intersects oncology with economic and financial perspectives, focusing on the impacts and risk factors associated with cancer.

The scientist's recent publications cover topics related to cancer research and economics. Notable papers include:

  • EP.04A.08 Leveraging the Quebec Lung Cancer Screening Program to Create a Collaborative Biobanking Project for Research Purposes, 2024, Journal of Thoracic Oncology
  • Abstract P4-14-02: Cohort study of women treated with chemotherapy for breast cancer during pregnancy compared with non-pregnant breast cancer patients, 2020, Cancer Research

Frequently collaborating with other researchers, Richard L. Theriault has worked alongside:

  • Sophie Plante
  • Sabrina Biardel
  • Andrea Mogas
  • Margaret Allard
  • Samuel Martel

Their contributions appear in specialist journals such as:

  • Journal of Thoracic Oncology
  • Cancer Research

Their research fields include oncology and economics and econometrics, reflecting a multidisciplinary approach.

Main topics of investigation in their work are:

  • Economic and Financial Impacts of Cancer
  • Cancer Risks and Factors

Best Publications

  • Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    S. Eva Singletary;Craig Allred;Pandora Ashley;Lawrence W. Bassett

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

    Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar

  • Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

    Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney

  • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

    Allan Lipton;Richard L. Theriault;Gabriel N. Hortobagyi;Joseph Simeone

  • Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel

    Nuhad K. Ibrahim;Neil Desai;Sewa Legha;Patrick Soon-Shiong

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

    Gabriel N. Hortobagyi;Richard L. Theriault;Allan Lipton;Lester Porter

  • The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial

    Jeffrey S. Wefel;Renato Lenzi;L D O Richard Theriault;Robert N. Davis

  • Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

    Richard L. Theriault;Allan Lipton;Gabriel N. Hortobagyi;Richard Leff

  • Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

    Nancy U. Lin;Ann Vanderplas;Melissa E. Hughes;Richard L. Theriault

  • Breast cancer: Clinical practice guidelines in oncology

    Robert W. Carlson;Benjamin O. Anderson;Harold J. Burstein;Charles E. Cox

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Management of Breast Cancer During Pregnancy Using a Standardized Protocol

    David L. Berry;Richard L. Theriault;Frankie A. Holmes;Valerie M. Parisi

  • High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

    Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

  • Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation

    Angela Katz;Eric A. Strom;Thomas A. Buchholz;Howard D. Thames

  • Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero

    Karin M.E. Hahn;Peter H. Johnson;Nancy Gordon;Henry Kuerer

  • Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

    Vicente Valero;Frankie A. Holmes;Ronald S. Walters;Richard L. Theriault

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Stephen B. Edge
Stephen B. Edge Roswell Park Cancer Institute
Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Jane C. Weeks
Jane C. Weeks Harvard University
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Eric P. Winer
Eric P. Winer Yale University
S. Eva Singletary
S. Eva Singletary The University of Texas MD Anderson Cancer Center
Clifford A. Hudis
Clifford A. Hudis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring healthcare careers beyond a traditional medical degree, there are several flexible online options to consider. For those interested in advanced practice roles without a nursing background, msn direct entry programs online offer a fast track to becoming a nurse leader, even for non-nursing graduates.

Entry-level nursing pathways are also widely accessible. Many students opt for accredited online adn programs, which provide foundational nursing education with greater flexibility—ideal for those balancing work or family commitments.

Not every healthcare career requires direct patient care. Administrative roles like medical billing and coding are in high demand and can be started quickly. If affordability is a key concern, consider choosing from online medical billing and coding schools that accept fafsa.

Admission processes vary: some nursing schools require prerequisite exams, while others do not. If you’re concerned about entrance tests, you may want to look for programs that answer the question, do you have to take the teas test to get into nursing school.

Best Scientists Citing Richard L. Theriault

Trending Scientists

Recently Published Articles